Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Phillips 66 — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.01 (market cap $29.60B), while Phillips 66 trades at $225 (market cap $89.52B). The key difference: Phillips 66 is far larger — about 3× Alnylam Pharmaceuticals, Inc.'s market cap, and Phillips 66 pays a 2.26% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PSX | |
|---|---|---|
Market Cap | $29.60B | $89.52B |
Sector | Health | Energy |
52-Week High | $491.22 | $225.58 |
52-Week Low | $205.48 | $122.17 |
Enterprise Value | $27.56B | $105.99B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Phillips 66 (PSX) trades at $225.48, up 4.62% today, with a bullish technical signal supported by moving averages and strong earnings beats. Recent Q2 2026 EPS of $9.41 exceeded expectations, driven by robust refining margins. The company announced a $5 billion joint venture for the Western Gateway Pipeline, signaling growth in midstream operations. Valuation metrics appear attractive with a P/E of 12.81 and P/S of 0.6, while profitability remains solid with a 24.02% ROE.
Outlook is positive due to sustained refining tightness and debt reduction, but risks include volatile crude prices and regulatory pressures. Analysts are bullish with a $221.92 consensus target, though the stock faces near-term resistance at $227. Revenue is projected to rebound to $152.2B in 2026, supporting a hold or buy stance for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
